摘要
CYP2C9基因多态性对口服香豆素类抗凝药、口服非甾体抗炎药、苯妥英等药物的代谢存在一定影响,本文基于大量现有研究进行综述,对口服香豆素类抗凝药、口服非甾体抗炎药、苯妥英等药物与CYP2C9基因多态性的关系进行阐述,旨在为个体化用药提供参考,为医院临床药学服务工作的拓展提供新思路。用药前若明确患者相关基因类型,便能在一定程度上减少不良反应的发生,为临床合理用药提供安全保障。
CYP2C9 gene polymorphism has a certain influence on the metabolism of oral coumarin anticoagulants,oral nonsteroidal anti-inflammatory drugs,phenytoin and other drugs.Based on a large number of existing studies,this paper reviewed the relationship between oral coumarin anticoagulants,oral nonsteroidal anti-inflammatory drugs,phenytoin and CYP2C9 gene polymorphism.The aim is to provide reference for individual drug use and new ideas for the development of clinical pharmaceutical care in clinic.If relevant gene types of patients are identified before medication,the occurrence of adverse reactions can be reduced to a certain extent and the safety guarantee for clinical rational drug use can be provided.
作者
贺思洁
张驰
He Sijie;Zhang Chi(Department of pharmacy,Maternal and Child Health Hospital of Hubei Province,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430070,China)
出处
《广东化工》
CAS
2022年第9期73-74,80,共3页
Guangdong Chemical Industry